News & Views | Published:

CANCER NANOMEDICINE

Winning the war with iron

An FDA-approved iron oxide nanoparticle used for the treatment of anaemia can be repurposed for leukaemia therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Crichton, R. in Iron Metabolism: From Molecular Mechanisms to Clinical Consequences (ed. Crichton, R.) 22–70 (Wiley, 2016).

  2. 2.

    Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N. & Torti, F. M. Annu. Rev. Nutr. 38, 97–125 (2018).

  3. 3.

    Daniels, T. R. et al. Biochim. Biophys. Acta 1820, 291–317 (2012).

  4. 4.

    Pinnix, Z. K. et al. Sci. Transl. Med. 2, 43ra56 (2010).

  5. 5.

    Gu, Z. et al. Cancer Res. 75, 2211–2221 (2015).

  6. 6.

    Trujillo-Alonso, V. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-019-0406-1 (2019).

  7. 7.

    Balakrishnan, V. S. et al. Eur. J. Clin. Invest. 39, 489–496 (2009).

  8. 8.

    Vadhan-Raj, S. et al. Am. J. Hematol. 89, 7–12 (2014).

  9. 9.

    Zanganeh, S. et al. Nat. Nanotechnol. 11, 986–994 (2016).

  10. 10.

    Schoenfeld, J. D. et al. Cancer Cell 32, 268 (2017).

  11. 11.

    Kalinowski, D. S. et al. Biochim. Biophys. Acta 1863, 727–748 (2016).

  12. 12.

    Toth, G. B. et al. Kidney Int. 92, 47–66 (2017).

Download references

Author information

Correspondence to Suzy V. Torti or Frank M. Torti.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Proposed mechanism by which ferumoxytol induces selective cell death in leukaemic cells that express low levels of FPN.